Table IV.
Comparison of treatment discontinuation and post-treatment in the sorafenib-I and sorafenib-II groups.
| Decision case | Sorafenib-I (n=11) | Sorafenib-II (n=9) | P-valuea |
|---|---|---|---|
| Discontinuation/continuation | 11/0 | 8/1 | 0.45 |
| Reason of discontinuation | |||
| Disease progression | 4 | 3 | 1.00 |
| Side effects | 7 | 5 | |
| Liver dysfunction | 2 | 1 | |
| Skin disorder | 2 | 2 | |
| Diarrhea | 2 | 2 | |
| Hepatic encephalopathy | 1 | 0 | |
| Post-treatment with HAIC | |||
| Yes | 2 (1)b | 6 (5)b | 0.02 |
| No | 9 (6)b | 2 (0)b | (0.02)b |
a
P-values were obtained by the Fisher’s exact test.
b
The number of patients whose treatment was interrupted by side effects is indicated in parentheses. HAIC, hepatic arterial infusion chemotherapy.